Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 2 (2) , 113-120
- https://doi.org/10.1016/s1542-3565(03)00318-5
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin productionGastroenterology, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Nonsteroidal anti-inflammatory drug gastropathyGastroenterology, 2000
- Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparisonPublished by Elsevier ,1999
- Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofenAlimentary Pharmacology & Therapeutics, 1999
- COX-2 inhibitorsThe Lancet, 1999
- Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effectsArthritis & Rheumatism, 1998
- Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory DrugsAnnals of Internal Medicine, 1995